SCHEDULE 13D/A: EcoR1 Capital Boosts Zymeworks Stake to 22.8% and Secures Board Representation

Investment firm EcoR1 Capital, along with its affiliates, has increased its beneficial ownership in Zymeworks Inc. to 22.8% and secured a board seat for its manager, Oleg Nodelman, signaling a deeper strategic involvement.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. collectively beneficially own 15,720,161 shares of Zymeworks Inc. common stock, representing 22.8% of the outstanding shares as of October 30, 2024.
• Oleg Nodelman, manager of EcoR1, was appointed to Zymeworks' board of directors on February 17, 2025. Another EcoR1 employee, Scott Platshon, is also on the board.
• The reporting persons acquired the stock for investment purposes, believing Zymeworks' common stock was undervalued and represented an attractive investment opportunity.
• Funds used working capital to purchase common stock and pre-funded warrants, totaling approximately $129,641,893.17 for common stock and $49,999,992.79 for pre-funded warrants.
• Recent purchases of common stock by the Funds occurred between January 13, 2025, and January 17, 2025, at dollar-weighted average prices ranging from $13.3946 to $14.0068 per share.
• The reporting persons hold 5,086,521 pre-funded warrants, which are subject to a 19.99% beneficial ownership limitation upon exercise.
• A Registration Rights Agreement requires Zymeworks to register the resale of warrant shares, with potential liquidated damages of 1% of the aggregate purchase price per 30-day period (up to 6% total) if registration statement filing or effectiveness deadlines are missed.

Sentiment

Score: 8

Explanation: The sentiment is positive due to a major institutional investor increasing its stake significantly and gaining board representation, signaling strong conviction in the company's value and potential for strategic influence. The investor explicitly states they believe the stock was undervalued.

Positives

• Significant increase in institutional ownership by EcoR1 Capital, indicating strong conviction in Zymeworks' value.
• Appointment of Oleg Nodelman, a representative of a major investor, to the board of directors, potentially enhancing corporate governance and strategic alignment.
• The investor's stated belief that Zymeworks' common stock was undervalued at the time of purchase suggests potential upside.
• The presence of two EcoR1 representatives on the board (Oleg Nodelman and Scott Platshon) provides substantial investor oversight and influence.

Risks

• The Pre-Funded Warrants are subject to a 19.99% beneficial ownership limitation, which restricts immediate full exercise and conversion into common stock.
• Potential for liquidated damages if Zymeworks fails to meet registration statement filing or effectiveness deadlines under the Registration Rights Agreement.
• The reporting persons may sell all or part of their holdings at any time, which could put downward pressure on the stock price.
• The reporting persons may enter into or unwind hedging or other derivative transactions, which could introduce volatility.

Future Outlook

The reporting persons intend to routinely monitor Zymeworks Inc. regarding various factors affecting their investment, including trading prices, operations, financial position, and strategic matters. They may purchase additional common stock, sell existing holdings, or engage in hedging transactions. While they have no present plans for major corporate actions, they may recommend actions to Zymeworks' management, board, and stockholders, potentially involving mergers, asset sales, changes in control, or other capitalization changes.

Management Comments

• "The reporting persons acquired the Stock for investment purposes based on their belief that the Issuer's Common Stock, when purchased, was undervalued and represented an attractive investment opportunity."
• "The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Common Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders."

Industry Context

This filing indicates a significant increase in a major institutional investor's stake and influence in Zymeworks, a biotechnology company. Such moves are common in the biotech sector where long-term investment and strategic guidance from experienced investors can be crucial for navigating complex R&D, clinical trials, and commercialization pathways. The appointment of a key investor's representative to the board suggests a more active role in shaping the company's strategic direction, which could be a positive signal for the market, especially if the company is perceived as undervalued or in need of strategic realignment.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Increased institutional ownership and board representation by a major investor could be seen as a positive signal, potentially leading to improved governance and strategic direction. However, the possibility of future share sales by the reporting persons could create selling pressure.
• Management/Employees: The increased influence of EcoR1 on the board may lead to strategic shifts or operational changes, potentially impacting management's autonomy and employee roles.
• Creditors: No direct impact mentioned, but improved financial health or strategic direction could indirectly benefit creditors.

Next Steps

• The reporting persons will routinely monitor Zymeworks Inc.'s operations, assets, prospects, financial position, and business development.
• The reporting persons may purchase additional common stock or sell existing holdings in the open market or privately.
• The reporting persons may enter into or unwind hedging or other derivative transactions.
• The reporting persons may communicate with other stockholders, industry participants, and interested parties about Zymeworks.
• The reporting persons may recommend actions to Zymeworks' management, board of directors, and stockholders, potentially involving significant corporate events.
• Zymeworks is obligated to file a registration statement for the resale of the warrant shares and use commercially reasonable efforts to cause it to become effective.

Key Dates

Recommendation

Keywords

Zymeworks Inc., EcoR1 Capital, Schedule 13D, Beneficial Ownership, Board Appointment, Biotechnology, Investment Firm, Shareholder Activism, Pre-Funded Warrants, Registration Rights